<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530682</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0409</org_study_id>
    <secondary_id>UF8074</secondary_id>
    <nct_id>NCT04530682</nct_id>
  </id_info>
  <brief_title>COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs</brief_title>
  <acronym>COVIDRIC-2</acronym>
  <official_title>Seroprevalence and Clinical Expression of SARS-CoV-2 Infection in Patients With Chronic Inflammatory Rheumatisms and Impact of Immuno-suppressive Drugs on the Persistence of Anti-SARS-CoV2 Antibodies During Two Years of Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Society of Rheumatology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accurate knowledge of the humoral immune responses induced by SARS-CoV-2 in patients&#xD;
      undergoing immunosuppressive therapy is essential to guide recommendations for infected&#xD;
      patients and for vaccination policy for uninfected immunosuppressed patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Longitudinal, cas-control study, observational multicenter study based on a cohort of 200&#xD;
      SARS-CoV-2 seropositive patients with chronic inflammatory rheumatisms (CIRs) from the&#xD;
      COVID-RIC-1 cohort.&#xD;
&#xD;
      The follow-up the persistence of SARS-CoV-2 serological status for 2 years in 200 patients&#xD;
      with inflammatory rheumatisms compared to matched 100 healthy controls to evaluate the impact&#xD;
      of immuno-suppressive therapy will be proposed.&#xD;
&#xD;
      Schedule: 4 visits over a 24-month period.&#xD;
&#xD;
      An observational routine care study was initiated in 16 French hospitals to assess the&#xD;
      SARS-CoV-2 seroprevalence in France in a population with CIRs (Covid-RIC-1). The project&#xD;
      plans to screen 5000 CIRs patients. The COVID-RIC-2 study will thus be proposed to these&#xD;
      pre-screened subjects according to their positive status in the serology for SARS-CoV-2 at&#xD;
      the time of their inclusion in COVID-RIC-1.&#xD;
&#xD;
      For the control group, 100 health professionals participating in the COVID-BIOTOUL cohort&#xD;
      will be selected to be matched on age, gender, and the time between the date of infection&#xD;
      with Covid-19 and the first serology of CIR patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of anti-SARS-CoV-2 neutralising immunoglobulin titres in patients with chronic inflammatory rheumatisms</measure>
    <time_frame>at baseline</time_frame>
    <description>Distribution of anti-SARS-CoV-2 neutralising immunoglobulin titres at baseline in patients with chronic inflammatory rheumatisms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of anti-SARS-CoV-2 neutralising immunoglobulin titres in patients with chronic inflammatory rheumatisms</measure>
    <time_frame>at 6 months after inclusion</time_frame>
    <description>Distribution of anti-SARS-CoV-2 neutralising immunoglobulin titres at 6 months in patients with chronic inflammatory rheumatisms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the maintenance of SARS-CoV-2 seroconversion in patients with chronic inflammatory rheumatisms (CIRs) compared to non-CIR controls.</measure>
    <time_frame>at 12 months after inclusion</time_frame>
    <description>To assess the maintenance of SARS-CoV-2 seroconversion at 12 months in patients with CIRs compared to non-CIR controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the maintenance of SARS-CoV-2 seroconversion at 24 month in patients with chronic inflammatory rheumatisms (CIRs) compared to non-CIR controls</measure>
    <time_frame>at 24 months after inclusion</time_frame>
    <description>To assess the maintenance of SARS-CoV-2 seroconversion at 24 months in patients with CIRs compared to non-CIR controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of the pandemic and its consequences on the psychological state of patients with chronic inflammatory rheumatisms</measure>
    <time_frame>baseline</time_frame>
    <description>Assess the impact at baseline of the pandemic and its consequences on the psychological state of patients with chronic inflammatory rheumatisms using different validated questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of the pandemic and its consequences on the psychological state of patients with chronic inflammatory rheumatisms</measure>
    <time_frame>at 6 month after inclusion</time_frame>
    <description>Assess the impact at 6 month of the pandemic and its consequences on the psychological state of patients with chronic inflammatory rheumatisms using different validated questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of the pandemic and its consequences on the psychological state of patients with chronic inflammatory rheumatisms</measure>
    <time_frame>at 12 month after inclusion</time_frame>
    <description>Assess the impact at 12 month of the pandemic and its consequences on the psychological state of patients with chronic inflammatory rheumatisms using different validated questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of the pandemic and its consequences on the psychological state of patients with chronic inflammatory rheumatisms</measure>
    <time_frame>at 24 month after inclusion</time_frame>
    <description>Assess the impact at 24 month of the pandemic and its consequences on the psychological state of patients with chronic inflammatory rheumatisms using different validated questionnaires</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Inflammatory Rheumatism</condition>
  <arm_group>
    <arm_group_label>SARS-CoV-2 seropositive patients with chronic inflammatory rheumatisms (CIRs)</arm_group_label>
    <description>200 SARS-CoV-2 seropositive patients with chronic inflammatory rheumatisms (CIRs) from the COVID-RIC-1 cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>100 health professionals participating in the COVID-BIOTOUL cohort will be selected to be matched on age, gender, and the time between the date of infection with Covid-19 and the first serology of CIR patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological samples</intervention_name>
    <description>Serum and plasma samples. At baseline, 6, 12 and 24 months</description>
    <arm_group_label>SARS-CoV-2 seropositive patients with chronic inflammatory rheumatisms (CIRs)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma samples at baseline. Serum samples at 0, 6, 12 and 24 months.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        200 participants with chronic inflammatory rheumatisms and positive status in the serology&#xD;
        for SARS-CoV-2. This population will be compared with a healthy control group from the&#xD;
        cohort Covid-Biotoul&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with rheumatoid arthritis or spondyloarthritis&#xD;
&#xD;
          -  With positive serology for SARS-CoV-2 infection less than 3 months old at the time of&#xD;
             inclusion&#xD;
&#xD;
          -  Under biotherapy, or conventional synthetic Disease-modifying antirheumatic drugs&#xD;
             (csDMARD) or Nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids for at least&#xD;
             one month during the year 2020&#xD;
&#xD;
          -  Agreeement to participate two years in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacques MOREL, MD, PhD</last_name>
    <phone>+33 467 337 791</phone>
    <email>j-morel@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hopsitalier universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>Occitanie</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques MOREL, MD, PhD</last_name>
      <phone>+33 467 337 791</phone>
      <email>j-morel@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV2</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Spondyloarthritis</keyword>
  <keyword>Seroprevalence</keyword>
  <keyword>Seropersistence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

